Skip to main content
. 2019 Feb 26;21(Suppl A):A6–A11. doi: 10.1093/eurheartj/suy028

Figure 3.

Figure 3

Prevalence of hyperkalaemia across heart failure trials (A). Discontinuation of study drug due to hyperkalaemic events across heart failure trials (B). Asterisk (*) denotes a definition of hyperkalaemia as >6.0 mEq/L.